Phathom Pharmaceuticals, Inc. Financials

Phathom Pharmaceuticals, Inc. (PHAT) reported $55.3M in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

No, Phathom Pharmaceuticals, Inc. (PHAT) reported a net income of -$334.3M in fiscal year 2024, with a net profit margin of -605.1%.

Phathom Pharmaceuticals, Inc. (PHAT) reported diluted earnings per share of $-5.29 for fiscal year 2024. This represents a -4.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Phathom Pharmaceuticals, Inc. (PHAT) had EBITDA of -$276.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2024, Phathom Pharmaceuticals, Inc. (PHAT) had $297.3M in cash and equivalents against $201.4M in long-term debt.

Phathom Pharmaceuticals, Inc. (PHAT) had a gross margin of 85.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

Phathom Pharmaceuticals, Inc. (PHAT) had an operating margin of -502.2% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

Phathom Pharmaceuticals, Inc. (PHAT) had a net profit margin of -605.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

Phathom Pharmaceuticals, Inc. (PHAT) generated -$266.9M in free cash flow during fiscal year 2024. This represents a -80.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Phathom Pharmaceuticals, Inc. (PHAT) generated -$266.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

Phathom Pharmaceuticals, Inc. (PHAT) had $378.3M in total assets as of fiscal year 2024, including both current and long-term assets.

Phathom Pharmaceuticals, Inc. (PHAT) invested $135K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

Phathom Pharmaceuticals, Inc. (PHAT) invested $34.1M in research and development during fiscal year 2024.

Phathom Pharmaceuticals, Inc. (PHAT) had 69M shares outstanding as of fiscal year 2024.

Phathom Pharmaceuticals, Inc. (PHAT) had a current ratio of 4.20 as of fiscal year 2024, which is generally considered healthy.

Phathom Pharmaceuticals, Inc. (PHAT) had a debt-to-equity ratio of -0.79 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Phathom Pharmaceuticals, Inc. (PHAT) had a return on assets of -88.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2024 data, Phathom Pharmaceuticals, Inc. (PHAT) had $297.3M in cash against an annual operating cash burn of $266.8M. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Phathom Pharmaceuticals, Inc. (PHAT) has negative shareholder equity of -$253.6M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Phathom Pharmaceuticals, Inc. (PHAT) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.

Phathom Pharmaceuticals, Inc. (PHAT) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.

Phathom Pharmaceuticals, Inc. (PHAT) has an interest coverage ratio of -3.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline.